Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Advances in risk-stratification in pediatric ALL

Anthony Moorman • 22 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia Imatinib

Anthony Moorman, PhD, Newcastle University, Newcastle, UK touches on advances in risk-stratification in pediatric acute lymphoblastic leukemia (ALL) including the significance of measurable residual disease (MRD) and identification of genomic variants. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Anthony Moorman

5:23
Redefining low risk high hyperdiploidy in pediatric ALL
Anthony Moorman • 8 Jun 2021
4:31
T-ALL diagnosis: cytogenetics, genomics and risk assessment
Anthony Moorman • 8 Jun 2021
2:44
Impact of genomics in the future of ALL treatment
Anthony Moorman • 8 Jun 2021
3:02
Enhanced risk stratification in pediatric ALL
Anthony Moorman • 10 Nov 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals